Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | HEXA | P06865 | 1/20 | 0.30 |
| ▸ | HEXB | P07686 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20105 | 0.79 | — | — | |
| SCHEMBL5287130 | 0.77 | NPC1 (0.41) | KDM4EKMT2AMEN1TP53GAA | |
| SCHEMBL11486230 | 0.77 | ALDH1A1 (0.39) | KDM4EKMT2AMEN1TP53POLB | |
| SCHEMBL1031810 | 0.75 | GRM5 (0.35) | KDM4EGAAL3MBTL1ALPL | |
| SCHEMBL22321405 | 0.75 | KDM4E (0.31) | KDM4E | |
| SCHEMBL5025746 | 0.74 | CYP2D6 (0.41) | KDM4EKMT2ALMNAPOLBRECQL | |
| SCHEMBL31632759 | 0.74 | NAAA (0.44) | KDM4EGAAMAPTALDH1A1 | |
| SCHEMBL31632699 | 0.74 | NAAA (0.44) | KDM4EGAAMAPTALDH1A1 | |
| SCHEMBL22192143 | 0.72 | KDM4E (0.35) | KDM4EKMT2AMEN1LMNATP53 | |
| SCHEMBL1717112 | 0.71 | PIK3CD (0.53) | KDM4EPOLBTDP1L3MBTL1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022152686-A1 | METHOD FOR REDUCING POLYURETHANE FOAM EMISSIONS | COVESTRO DEUTSCHLAND AG (DE) | 2022-07-21 | — | — | WO | claimed |
| EP-4029893-A1 | METHOD FOR REDUCING EMISSIONS OF POLYURETHANES | Covestro Deutschland AG (DE) | 2022-07-20 | — | — | EP | claimed |
| WO-2022023229-A1 | CURABLE COMPOSITIONS AND PRODUCTS FORMED THEREFROM, AND METHODS OF FORMING THE SAME | COVESTRO DEUTSCHLAND AG (DE) | 2022-02-03 | — | — | WO | claimed |
| EP-3945101-A1 | CURABLE COMPOSITIONS AND PRODUCTS FORMED THEREFROM, AND METHODS OF FORMING THE SAME | Covestro Deutschland AG (DE) | 2022-02-02 | — | — | EP | claimed |
| EP-3921312-A1 | CURABLE COMPOSITIONS, PRODUCTS AND ARTICLES FORMED THEREFROM, AND METHODS OF FORMING THE SAME | Covestro LLC (US) | 2021-12-15 | — | — | EP | claimed |
| EP-3218423-B1 | COMB POLYURETHANE DISPERSANTS | HUNTSMAN PETROCHEMICAL LLC (US) | 2021-01-06 | — | — | EP | claimed |
| US-10793667-B2 | Curable compositions, products and articles formed therefrom, and methods of forming the same | COVESTRO DEUTSCHLAND AG (DE) | 2020-10-06 | — | — | US | claimed |
| WO-2020163464-A1 | CURABLE COMPOSITIONS, PRODUCTS AND ARTICLES FORMED THEREFROM, AND METHODS OF FORMING THE SAME | COVESTRO LLC (US) | 2020-08-13 | — | — | WO | claimed |
| US-20200255585-A1 | CURABLE COMPOSITIONS, PRODUCTS AND ARTICLES FORMED THEREFROM, AND METHODS OF FORMING THE SAME | COVESTRO LLC | 2020-08-13 | — | — | US | claimed |
| EP-3218423-A1 | COMB POLYURETHANE DISPERSANTS | Huntsman Petrochemical LLC (US) | 2017-09-20 | — | — | EP | claimed |
| EP-1517938-B1 | CATHODIC ELECTROCOATING COMPOSITION CONTAINING MORPHOLINE DIONE BLOCKED POLYISOCYANATE CROSSLINKING AGENT | DU PONT (US) | 2007-10-31 | — | — | EP | claimed |
| US-7183360-B2 | Method for crosslinking hydrogels with morpholine-2,3-diones | BASF AKTIENGESELLSCHAFT (DE) | 2007-02-27 | — | — | US | claimed |
| US-6908539-B2 | For use in curing a neutralized epoxy-amine adduct | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2005-06-21 | — | — | US | claimed |
| EP-1517938-A1 | CATHODIC ELECTROCOATING COMPOSITION CONTAINING MORPHOLINE DIONE BLOCKED POLYISOCYANATE CROSSLINKING AGENT | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2005-03-30 | — | — | EP | claimed |
| EP-1436335-B1 | METHOD FOR CROSSLINKING HYDROGELS WITH MORPHOLINE-2,3-DIONES | BASF AG (DE) | 2005-01-26 | — | — | EP | claimed |
| US-20040231065-A1 | Method for crosslinking hydrogels with morpholine-2,3-diones | BASF AKTIENGESELLSCHAFT, A GERMAN CORPORATION (DE) | 2004-11-25 | — | — | US | claimed |
| EP-1436335-A1 | METHOD FOR CROSSLINKING HYDROGELS WITH MORPHOLINE-2,3-DIONES | BASF AKTIENGESELLSCHAFT (DE) | 2004-07-14 | — | — | EP | claimed |
| WO-2004005366-A1 | CATHODIC ELECTROCOATING COMPOSITION CONTAINING MORPHOLINE DIONE BLOCKED POLYISOCYANATE CROSSLINKING AGENT | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2004-01-15 | — | — | WO | claimed |
| US-20040003995-A1 | Cathodic electrocoating composition containing morpholine dione blocked polyisocyanate crosslinking agent | E. I. DU PONT DE NEMOURS AND COMPANY | 2004-01-08 | — | — | US | claimed |
| WO-2003031482-A1 | METHOD FOR CROSSLINKING HYDROGELS WITH MORPHOLINE-2,3-DIONES | BASF AKTIENGESELLSCHAFT (DE) | 2003-04-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040231065-A1 | Method for crosslinking hydrogels with morpholine-2,3-diones | ADM2, COL1A1, MDN1 | KDM4E 3022/4885KMT2A 3242/4885MEN1 2011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.